CRVO CervoMed Inc.
$2.22▼ -0.89%
Healthcare
Other
After hours
$2.21▼ -0.45%
Oct 27, 4:46 PM ET
Volume 148.5K
Avg Volume (10D) 206.4K
Key Metrics & Fundamentals
Market Cap
$33.56M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.13 - 10.00
% vs 50 MA
-14.56%
% vs 200 MA
-38.21%
RSI-14
37.6
MACD Histogram
-0.0500
Beta (1Y vs SPY)
1.77
Free Cash Flow
-$6.92M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$6.68M
COGS
–
Operating Exp
$6.68M
Operating Income
-$6.68M
EBIT
-$6.68M
Pretax Income
-$6.57M
Net Income
-$6.57M
EPS (Diluted)
-0.64
Price & Volume History
Loading chart…
Recent News
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
GlobeNewswire · Oct 12, 2026 7:30 AM ET
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
GlobeNewswire · Sep 28, 2026 7:30 AM ET
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
GlobeNewswire · Sep 22, 2026 7:30 AM ET
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
GlobeNewswire · Sep 10, 2026 7:30 AM ET
CervoMed to Participate in September Investor Conferences
GlobeNewswire · Sep 8, 2026 7:30 AM ET
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
GlobeNewswire · Aug 5, 2026 7:30 AM ET
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
GlobeNewswire · Aug 4, 2026 5:15 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See CRVO's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.